Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;199(1):e32133.
doi: 10.1002/ajmg.c.32133. Epub 2025 Feb 14.

Growth and Growth-Promoting Treatments in Turner Syndrome

Roopa Kanakatti Shankar  1   2 , Charmian A Quigley  3 , Tsuyoshi Isojima  4 , Nelly Mauras  5 , Steven D Chernausek  6 , Malgorzata Wasniewska  7 , Theo C J Sas  8
Affiliations
Review

Growth and Growth-Promoting Treatments in Turner Syndrome

Roopa Kanakatti Shankar et al. Am J Med Genet C Semin Med Genet. 2025 Mar.

Abstract

Short stature is a common presenting feature and an important concern for families of children with Turner syndrome. In this review, we summarize the data that shaped the updated international consensus guidelines for Turner syndrome published in 2024. The natural history of growth in Turner syndrome, the safety and efficacy of recombinant human growth hormone therapy, and the alternate growth promoting agents under consideration are presented. Timely, adequate growth hormone therapy can counter growth failure in childhood, promote catch-up growth and help many individuals with Turner syndrome attain a near-normal adult height. However, individual responses to growth hormone treatment are highly variable and are influenced by factors such as parental heights, age, baseline height, timing of estrogen initiation and pubertal status. Shared decision making on initiation of treatment, a candid conversation regarding the modest gradual height gain resulting from growth hormone therapy, and individualization of therapeutic goals can facilitate realistic expectations of growth promoting therapy in Turner syndrome.

Keywords: IGF‐I; growth; growth hormone; height velocity; turner syndrome.

PubMed Disclaimer

References

    1. Amundson, E., U. W. Boman, M.‐L. Barrenäs, I. Bryman, and K. Landin‐Wilhelmsen. 2010. “Impact of Growth Hormone Therapy on Quality of Life in Adults With Turner Syndrome.” Journal of Clinical Endocrinology and Metabolism 95, no. 3: 1355–1359. https://doi.org/10.1210/jc.2009‐1754.
    1. Attie, K. M., J. R. Julius, C. Stoppani, and A. C. Rundle. 1997. “National Cooperative Growth Study Substudy VI: The Clinical Utility of Growth‐Hormone‐Binding Protein, Insulin‐Like Growth Factor I, and Insulin‐Like Growth Factor‐Binding Protein 3 Measurements.” Journal of Pediatrics 131, no. 1 Pt 2: S56–S60. https://doi.org/10.1016/s0022‐3476(97)70013‐1.
    1. Backeljauw, P., J. C. Blair, J.‐M. Ferran, et al. 2023. “Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and ANSWER Program.” Journal of Clinical Endocrinology and Metabolism 108: 2653–2665. https://doi.org/10.1210/clinem/dgad159.
    1. Backeljauw, P., S. Kanumakala, S. Loche, et al. 2021. “Safety and Effectiveness of Recombinant Human Growth Hormone in Children With Turner Syndrome: Data From the PATRO Children Study.” Hormone Research in Pædiatrics 94, no. 3–4: 133–143. https://doi.org/10.1159/000515875.
    1. Bannink, E. M. N., H. Raat, P. G. H. Mulder, and S. M. P. F. de Muinck Keizer‐Schrama. 2006. “Quality of Life After Growth Hormone Therapy and Induced Puberty in Women With Turner Syndrome.” Journal of Pediatrics 148, no. 1: 95–101. https://doi.org/10.1016/j.jpeds.2005.08.043.

Substances

LinkOut - more resources